Paul F. Schellhammer, MD, a member of the Urology Times editorial council, is professor of urology and program director of the Virginia Prostate Center of the Eastern Virginia Medical School and Sentara Cancer Institute, Norfolk.
Bladder cancer studies help pinpoint risk of recurrence
Progression-free curves for N0 disease were improved when more than eight to 10 nodes per side were removed.
Data shed light on salvage RT, immediate hormone Tx
I believe the evidence is accumulating in favor of earlier [androgen deprivation] therapy to provide a survival benefit.
ThuFLEP and M-HoLEP achieve comparable functional outcomes in BPH
Home instillation of mitomycin intravesical solution found feasible, safe in NMIBC
Study shows persistent bone protective effect of menopausal hormone therapy
Metastasis-directed radiotherapy without systemic therapy yields promising outcomes in oligometastatic ccRCC